Product Information
MOUNJARO 10 MG/0.5 ML PEN is a brand product labeled by Eli Lilly and Company, priced at $538.6836 per ML under NDC 00002147180. Its NADAC has been published 211 times since Sep 21, 2022.
FDA first approved this application on May 13, 2022.
Strength
10 mg/.5mL
Manufacturer
Eli Lilly and CompanyNDC
00002147180
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
TIRZEPATIDEApproval Type
New Drug (NDA)
FDA Application
NDA215866FDA Approved
5/13/2022
On Market Since
5/13/2022
Pharmacological Classes
Price Statistics
The NADAC for MOUNJARO 10 MG/0.5 ML PEN has been published 211 times since Sep 21, 2022, and over the history we have for it it has risen 15.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $538.6836 per ML |
|---|---|
| All-time high | $538.7255 (Jun 10, 2026) |
| All-time low | $467.2742 (Sep 21, 2022) |
| 52-week high | $538.7255 |
| 52-week low | $522.9373 |
| Median price | $515.7277 |
| Average price | $511.8153 |
| Largest weekly change | +5.0% (Jan 11, 2023) |
| Weeks tracked | 211 |
| Tracking since | Sep 21, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tirzepatide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MOUNJARO 10 MG/0.5 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for MOUNJARO 10 MG/0.5 ML PEN, manufactured by Eli Lilly and Company, is $538.6836 per ML (NDC 00002147180), effective Sep 30, 2026.
How has the price of MOUNJARO 10 MG/0.5 ML PEN changed over time?
Over the history we have for it, the NADAC for MOUNJARO 10 MG/0.5 ML PEN has risen 15.3%. It has been tracked across 211 weekly CMS publications since Sep 21, 2022.
What are the highest and lowest recorded NADAC prices for MOUNJARO 10 MG/0.5 ML PEN?
Since Sep 21, 2022, the NADAC for MOUNJARO 10 MG/0.5 ML PEN has ranged from a low of $467.2742 (Sep 21, 2022) to a high of $538.7255 (Jun 10, 2026), with a median of $515.7277 per ML.
Are there cheaper alternatives to MOUNJARO 10 MG/0.5 ML PEN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZEPBOUND 10 MG/0.5 ML PEN, is $526.0461 per ML — about 2% below MOUNJARO 10 MG/0.5 ML PEN.
Who manufactures MOUNJARO 10 MG/0.5 ML PEN?
MOUNJARO 10 MG/0.5 ML PEN (NDC 00002147180) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.